LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.23 -4.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.21

Max

1.29

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+69.17% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-20M 155M
Eelmine avamishind	5.88
Eelmine sulgemishind	1.23

Uudiste sentiment

By Acuity

50%

147 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. märts 2026, 19:18 UTC

Suurimad hinnamuutused turgudel

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11. märts 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11. märts 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11. märts 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11. märts 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11. märts 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11. märts 2026, 21:47 UTC

Tulu

Liontown Resources: Market Tailwinds Strengthening Outlook

11. märts 2026, 21:46 UTC

Tulu

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources Says FY26 Guidance Unchanged

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources 1H Unit Operating Costs A$985/Ton

11. märts 2026, 21:44 UTC

Tulu

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Revenue A$207.5 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Net Loss A$184 Million

11. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss $7.5M >VGZ

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss/Shr 6c >VGZ

11. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11. märts 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11. märts 2026, 20:26 UTC

Tulu

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11. märts 2026, 20:19 UTC

Uudisväärsed sündmused

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11. märts 2026, 20:15 UTC

Tulu

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11. märts 2026, 19:31 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11. märts 2026, 19:01 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11. märts 2026, 18:59 UTC

Omandamised, ülevõtmised, äriostud

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

69.17% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 69.17%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

147 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.